Both in Pharmaceuticals
Zymeworks vs Aurinia Pharmaceuticals
Over the past year ZYME returned +53.5% and AUPH returned +22.6%; their daily moves had a correlation of 0.24.
ZYME +53.5% AUPH +22.6%Growth of $1, one year, split-adjusted
| Metric | ZYME | AUPH |
|---|---|---|
| Price | $28.99 | $16.14 |
| Market cap | $2.08B | $2.16B |
| Today | +1.33% | −3.06% |
| 1 month | +15.3% | +2.0% |
| 6 months | +8.3% | +2.3% |
| Year to date | +10.1% | +1.2% |
| 1 year | +51.6% | +33.2% |
| Revenue growth (YoY) | −90.6% | +13.9% |
| Gross margin | 100.0% | 90.1% |
| Net margin | −980.8% | 37.9% |
| P/E (TTM) | — | 6.9× |
| Price / sales | 56.1× | 6.7× |
| Net cash | $270.7M | $431.7M |
| Dividend yield | — | — |
| Volatility (60d) | 46.5% | 30.4% |
| Short % of float | 13.0% | 7.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).